CMML Leukemia Survival Rate by Age: What to Know

Survival in chronic myelomonocytic leukemia (CMML) varies substantially by age, but the relationship is not as straightforward as “older equals worse.” A large U.S. population study found that patients aged 80 and older faced roughly three-and-a-half times the risk of death compared to the youngest patients, while those between 60 and 79 had about twice the risk. Yet age is just one piece of a much larger puzzle that includes disease subtype, specific gene mutations, and treatment decisions. Understanding how these factors interact is more useful than any single survival number.

How Age Affects CMML Survival in Population Data

The clearest picture of age-related survival comes from the SEER database, which tracks cancer outcomes across the United States over decades. An analysis of CMML patients over a twenty-year period found that age 80 and above was one of the strongest predictors of death. Compared to younger patients, those 80 and older had a hazard ratio of 3.65 for overall mortality and 3.01 for cancer-specific mortality. Patients aged 60 to 79 also faced elevated risk, with an overall mortality hazard ratio of about 1.85.¹

For younger adults, the numbers look somewhat different. A study focusing on patients under 65 with CMML found a median overall survival of about 55 months, with 84% alive at one year and 45% alive at five years. At ten years, roughly a quarter of patients were still alive.² These are considerably better numbers than the median of roughly one year often cited for older populations diagnosed later in the disease course.

Interestingly, a recent study comparing patients aged 50 and younger to those over 50 found that when you remove the effect of stem cell transplantation from the analysis, median survival was 3.7 years in both groups. The younger patients had very different biology under the hood, with distinct mutation patterns and more frequent organ enlargement, but these differences did not translate into better or worse raw survival when transplant was excluded.³ This finding suggests that much of the survival advantage seen in younger patients in broader datasets reflects their eligibility for transplant rather than inherently less aggressive disease.

Dysplastic Versus Proliferative Subtypes

CMML is not one disease. It splits into two clinically important subtypes based on the white blood cell count at diagnosis. The dysplastic form (sometimes abbreviated dCMML) looks more like a myelodysplastic syndrome, with lower white cell counts and features of ineffective blood cell production. The proliferative form (pCMML) behaves more like a myeloproliferative neoplasm, with higher white cell counts, circulating immature cells, and often an enlarged spleen. This distinction matters more for prognosis than many people realize.

In a large international cohort, median overall survival was 30 months for the dysplastic subtype compared to 19 months for the proliferative subtype. The proliferative group also carried a higher frequency of mutations in the RAS signaling pathway and the ASXL1 gene, both associated with worse outcomes.⁴ This subtype classification can be more informative than the WHO’s morphologic grading into CMML-0, CMML-1, and CMML-2, which is based on blast counts. In the younger-patient study, median survival for CMML-1 was 59 months versus 24 months for CMML-2, showing that blast percentage does still have prognostic weight even in a younger population.²

The subtype distinction also has concrete implications for transplant. In one study, patients with the dysplastic form who underwent stem cell transplant had dramatically better outcomes: a median overall survival of 8.6 years compared to just 0.9 years for those with the proliferative subtype. Relapse-free survival was also several times longer in the dysplastic group.⁵ If you or someone you know is being evaluated for transplant, the subtype designation should be part of that conversation.

Gene Mutations That Shift the Prognosis

Two genes in particular have emerged as powerful predictors of how CMML behaves: ASXL1 and TET2. These are not exotic discoveries but among the most commonly mutated genes in the disease, and the interplay between them creates a useful shorthand for risk.

Patients with a TET2 mutation but no ASXL1 mutation fare best, with a median survival of roughly 38 to 54 months depending on the study cohort. Everyone else falls into a considerably worse tier. Patients with an ASXL1 mutation but no TET2 mutation have the shortest median survival, around 20 to 21 months. Those with mutations in both genes, or neither gene, land somewhere in between and perform similarly to each other.⁶⁷

This matters for how you interpret age-related survival data. Older patients tend to carry TET2 and SRSF2 mutations at much higher rates, while younger patients more often harbor PTPN11 mutations and lack TET2 changes altogether.³ On one hand, an older patient with an isolated TET2 mutation (no concurrent ASXL1 mutation) might have a better molecular profile than a younger patient with an ASXL1 mutation. On the other hand, the older patient faces competing health problems that erode their advantage. The net effect is that age and genetics each exert their own independent force on survival, and neither one tells the full story by itself.

Risk Scoring Models That Combine Everything

Because so many variables matter, hematologists have developed scoring systems that combine clinical and molecular data. The most comprehensive is the CPSS-Mol (Clinical/Molecular CMML Prognostic Scoring System), which integrates factors like blood counts, disease subtype, cytogenetic findings, and specific gene mutations into a single risk score. It divides patients into four risk groups, with median overall survival ranging from over 12 years in the lowest-risk group down to about 18 months in the highest-risk group.⁸

That spread, from over a decade to under two years, is wider than the survival range explained by age alone. It underscores why asking “what is the survival rate for my age group” is an incomplete question. A 72-year-old in the lowest CPSS-Mol risk category can expect a very different trajectory than a 72-year-old in the highest risk category, even though a population-level survival table would place them in the same age bracket.

Transformation to Acute Leukemia

One of the most feared complications of CMML is its progression to acute myeloid leukemia (AML). About 15 to 20 percent of CMML patients will transform over three to five years, though some estimates run as high as 30 percent depending on the patient population studied.⁹¹⁰ This transformation rate is substantially higher than what’s seen in myelodysplastic syndromes (MDS). In one comparative study using Medicare-linked data, about 43% of CMML patients progressed to AML versus roughly 16% of MDS patients, and the time to progression was shorter as well.¹¹

Once CMML converts to AML, survival drops sharply. This is part of why the CPSS-Mol model assigns heavy weight to leukemic transformation risk. Patients in the highest-risk category have a roughly 48% chance of progressing to AML within four years, versus essentially zero for those in the lowest-risk group.⁸

How Treatment Choices Affect Survival

For most CMML patients who are not transplant candidates, the main treatment involves hypomethylating agents (HMAs) such as azacitidine and decitabine. These drugs do not cure the disease but can improve blood counts and delay progression. In a large population-based study of older CMML patients, those who received HMAs had a median survival of about 17 to 19 months compared to 11 months for matched patients who did not.¹² That improvement is real but modest, and it has to be weighed against side effects and the demands of treatment cycles.

The only potentially curative treatment for CMML is allogeneic stem cell transplantation, where a donor’s blood-forming stem cells replace the patient’s own. This option is largely confined to younger, fitter patients because of the procedure’s intensity and risk. In one study of transplanted patients, about 31% had died at a median follow-up of roughly six years, with relapse and treatment-related complications splitting the causes of death roughly evenly.¹³ That means a majority of transplanted patients were alive years out, which is a fundamentally different picture from the disease’s natural history. But the price of eligibility is being young and healthy enough to survive the procedure itself, and the price of failure can be severe graft-versus-host disease or relapse.

The distinction between the dysplastic and proliferative subtypes matters here too. As noted earlier, transplant outcomes diverge dramatically between the two subtypes, with the proliferative form carrying much higher relapse and treatment-related mortality rates.⁵

How CMML Compares to MDS in Older Adults

CMML is sometimes discussed alongside MDS because the two share overlapping features and were once classified together. But outcomes are consistently worse for CMML. In a direct comparison of older patients using population data, CMML carried a median survival of about 13 months versus 23 months for MDS. The three-year survival rate was 19% for CMML and 36% for MDS. Even after adjusting for baseline health and treatment, CMML was associated with more than double the risk of progressing to AML or dying.¹¹

Part of the survival gap reflects biology: CMML’s myeloproliferative features drive more rapid disease evolution. But part of it may be structural. The same study found that CMML patients were less frequently treated than MDS patients, possibly because CMML occupies an awkward diagnostic space between MDS and MPN and has historically attracted less treatment-protocol development. That treatment gap has narrowed somewhat with increased HMA use but has not disappeared.

Why CMML Is So Closely Tied to Aging

CMML is overwhelmingly a disease of older adults, with a median age at diagnosis in the early to mid-70s. This is not a coincidence. Research has shown that many of the genes commonly mutated in CMML, including TET2, ASXL1, and DNMT3A, are the same genes that accumulate mutations as people age in a process called age-related clonal hematopoiesis. As the blood-forming system gets older, it naturally shifts toward producing more cells of the myeloid and monocytic lineages. The current model suggests CMML may represent what happens when enough of these age-related mutations accumulate in one person’s bone marrow to tip the balance from normal aging into a leukemic state.¹⁴

Most CMML patients carry mutations in at least two of these aging-associated genes, and over half carry seven or more total mutations. This high mutation burden helps explain why CMML is rare before age 50 and why the under-50 cases that do occur have such a different molecular fingerprint: those younger patients are not riding the same wave of accumulated aging mutations and instead tend to arrive at CMML through different genetic routes.

Factors Beyond Biology That Influence Survival

The SEER database analysis also uncovered non-biological factors linked to worse outcomes. Male sex carried modestly elevated risk. Being single or widowed at diagnosis was associated with roughly 30% higher overall mortality compared to being married. Even geography played a role: patients in mid-sized metropolitan areas had slightly worse outcomes than those in the largest cities, possibly reflecting differences in access to specialized hematology centers.¹

These findings are a reminder that survival statistics are population averages shaped not just by the biology of the cancer but by who has the social support, insurance coverage, and proximity to expert care needed to navigate a rare and complex diagnosis. For a disease as uncommon as CMML, the gap between being treated at a center that sees many cases per year and one that sees only a handful can be meaningful.

Emerging Therapies and the Research Landscape

CMML has historically been treated with therapies borrowed from MDS or MPN, and the pipeline of CMML-specific treatments has been thin. That is starting to change, though slowly. One of the more studied newer agents is tagraxofusp, which targets CD123, a protein found on CMML cells. In a phase 1/2 trial, the drug showed a manageable safety profile and was effective at shrinking enlarged spleens, but it did not produce complete or partial remissions by standard response criteria. Median overall survival in treated patients was about 11 to 16 months depending on the subgroup.¹⁵ That result is honest: limited clinical efficacy, though the spleen responses were notable for patients dealing with painful organ enlargement.

Other agents are earlier in development. STX-0712, a small-molecule therapy, recently received fast-track designation from the FDA for relapsed or refractory CMML and is being evaluated in a phase 1 dose-escalation trial. Results are not yet available, but the designation signals regulatory acknowledgment that CMML patients need better options. The broader trend in hematology toward mutation-targeted therapies, particularly those aimed at RAS-pathway mutations, could eventually benefit the subset of CMML patients who carry those genetic changes. For now, clinical trials remain one of the most important avenues for patients whose disease has stopped responding to HMAs and who are not transplant candidates.